Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 1Neoplasms 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

pembrolizumab 3spartalizumab 2trametinib 1tislelizumab 1palbociclib 1nazartinib 1milademetan 1enzalutamide 1devimistat 1dehydroftorafur 1canakinumab 1binimetinib 1bemarituzumab 1aldesleukin 1Specimen Handling 1Pentostatin 1Midazolam 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Interleukin-2 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Early Intervention, Educational 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × nazartinib × Gastrointestinal × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔